ReviewFrontiers in endocrinology2026
Dysfunction and therapeutic potential of brown adipose tissue and batokines in obesity and type 2 diabetes mellitus.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity and Type 2 Diabetes Mellitus (T2D) remain key drivers of premature mortality, morbidity, and healthcare expenditure globally. Although we have witnessed dramatic recent advances in our therapeutic armamentarium for these conditions (most notably regarding the latest iterations of the Glucagon-like Peptide-1 [GLP-1] class of therapies), there remain important unmet needs in our current management approach. Brown adipose tissue (BAT) and its associated batokines (molecules release from BAT) plays a key role in the regulation of energy expenditure and glucose and lipid metabolism. Multiple lifestyle factors (most notably cold exposure and certain nutrients) can activate BAT via activation of the systemic nervous system (SNS). In the context of obesity and T2D, BAT activity is downregulated through multiple complex processes. This downregulation further promotes insulin resistance and dysregulation of metabolic regulation that contributes towards ongoing pathogenesis of these pernicious conditions, in a vicious circle. In such a scenario, it would be desirable to break this vicious circle through novel therapies that target the BAT-batokine axis. In recent times, there has been a transformation of our insights into this approach, particularly from data derived from rodent models. Beyond facilitating weight loss and improved metabolic efficiency and flexibility, such a novel approach to therapy that targets the BAT-batokine axis would improve glucose and lipid regulation but also have potential for organ-specific therapeutic benefits, including in the heart, lung, kidney, and liver. Furthermore, such an approach holds great promise to improve body composition (to reduce adiposity whilst preserving or even enhancing skeletal muscle mass and function), due to the therapeutic effects being independent of negative energy balance. The BAT-batokine axis has finally come of age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.